List of Excipients in Branded Drug FEMHRT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	FEMHRT	norethindrone acetate/ethinyl estradiol	0430-0145	CALCIUM STEARATE
Allergan Inc	FEMHRT	norethindrone acetate/ethinyl estradiol	0430-0145	CELLULOSE, MICROCRYSTALLINE
Allergan Inc	FEMHRT	norethindrone acetate/ethinyl estradiol	0430-0145	LACTOSE MONOHYDRATE

FEMHRT Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

FEMHRT is an oral, fixed-dose hormone replacement therapy containing norethindrone acetate and ethinyl estradiol. Its commercial opportunity is no longer centered on core molecule exclusivity. The relevant opportunities are generic substitution, differentiated tablet manufacture, excipient qualification, supply reliability, and reformulation for patients who need alternatives to lactose, colorants, or conventional immediate-release tablets.

FEMHRT has two marketed strengths:

Product	Norethindrone acetate	Ethinyl estradiol	Dosage form
FEMHRT low dose	0.5 mg	2.5 mcg	Oral tablet
FEMHRT standard dose	1 mg	5 mcg	Oral tablet

The product is indicated for menopausal vasomotor symptoms and vulvar or vaginal atrophy associated with menopause. It carries the class-wide risks applicable to systemic estrogen and estrogen-progestin products, including cardiovascular events, thromboembolic disease, breast cancer, and endometrial cancer risk described in labeling.[1]

What excipients are used in FEMHRT tablets?

FEMHRT is an immediate-release compressed tablet. Public labeling identifies the inactive ingredients used in the product, although the exact quantitative composition and manufacturing process are generally proprietary.

Historical labeling identifies excipient classes including lactose, starch-based disintegrants or fillers, povidone, magnesium stearate, and coloring agents. Exact ingredient combinations can vary by manufacturer, strength, market, and manufacturing site. Commercial teams should use the applicable current FDA label and DailyMed record as the controlling source for a specific product presentation.[1,2]

Functional role of the excipients

Excipient class	Likely function in FEMHRT-type tablets	Commercial relevance
Lactose or another soluble filler	Tablet bulk and compression properties	Creates a lactose-free product opportunity
Corn starch or pregelatinized starch	Filler, disintegrant, or binder	Affects tablet breakup and manufacturability
Povidone	Binder and granulation aid	Supports low-dose uniformity
Magnesium stearate	Lubricant	Excess use can slow dissolution
Colorants	Strength identification and product appearance	Supports line clearance and differentiation
Film-coating materials, where used	Protection, appearance, swallowability	May support a more patient-friendly presentation

The active ingredients are present at very low levels relative to tablet mass. This makes blend uniformity, segregation control, and content-uniformity testing more important than the raw material cost of the active pharmaceutical ingredients.

What excipient strategy is appropriate for FEMHRT generics?

The strongest strategy is a Q1/Q2-compatible formulation that preserves the reference product’s critical quality attributes while removing avoidable excipient barriers.

A generic developer should initially target:

1. Equivalent dosage strengths.
2. Immediate-release performance.
3. Comparable tablet dimensions and weight.
4. Similar dissolution across physiologic pH conditions.
5. Robust content uniformity for ethinyl estradiol.
6. A simple excipient system with reliable global supply.

Under the FDA abbreviated new drug application pathway, the applicant must identify inactive ingredients and demonstrate that the formulation is acceptable for the dosage form and route of administration. The formulation must also meet pharmaceutical-equivalence and bioequivalence requirements.[3]

Preferred formulation architecture

A practical platform can use:

• Lactose monohydrate or an alternative filler.
• Microcrystalline cellulose where improved compactability is needed.
• Low-substituted hydroxypropyl cellulose or crospovidone as a disintegrant.
• Povidone or hydroxypropyl cellulose as a binder.
• Magnesium stearate or sodium stearyl fumarate as a lubricant.
• A permitted colorant or color-free approach for strength identification.

The principal technical risk is not dissolution alone. It is achieving uniform distribution of the microgram-level ethinyl estradiol component across the powder blend and maintaining that distribution during transfer and compression.

What commercial opportunities exist for lactose-free FEMHRT products?

A lactose-free product is the clearest excipient-led opportunity. Lactose-free substitution can address patients with lactose intolerance, excipient avoidance preferences, and pharmacy requests for a differentiated generic.

Suitable alternatives include microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch derivatives, and selected co-processed excipients. Each alternative changes tablet density, moisture sensitivity, compression force, disintegration, and dissolution.

Commercial advantages

A lactose-free product could support:

• Preferred-product status with selected pharmacy benefit managers.
• Contract manufacturing for companies seeking a differentiated generic.
• Hospital and health-system formulary procurement.
• Export registration in markets with different excipient labeling expectations.
• A clean-label positioning strategy, subject to regulatory and promotional limits.

The economic value depends on the size of the FEMHRT market, the number of approved ANDA products, reimbursement terms, and the ability to secure substitution or formulary placement. The product’s relatively low active dose does not automatically create pricing power.

How can excipients improve FEMHRT manufacturing economics?

Excipient optimization can reduce cost through process control rather than through low unit price alone.

Direct cost levers

Manufacturing issue	Excipient response	Expected benefit
Poor blend uniformity	Use ordered mixing, carrier-based premix, or co-processed filler	Lower content-uniformity risk
Capping or lamination	Improve binder and filler balance	Fewer compression rejects
Slow dissolution	Reduce hydrophobic lubricant exposure or optimize disintegrant	More consistent release
Moisture sensitivity	Select lower-moisture or moisture-tolerant excipients	Better stability
Weight variability	Use excipients with tighter particle-size distribution	Improved compression control
Multi-site supply risk	Qualify dual-source excipients	Lower interruption risk

The use of a co-processed excipient may simplify tableting, but it can increase regulatory documentation and create supplier dependency. A simple, widely available excipient system is generally preferable for a mature generic product unless the process problem justifies a more specialized platform.

What formulation patents protect FEMHRT?

FEMHRT’s commercial position is primarily associated with the active combination and approved product history rather than with a high-value modern excipient patent platform.

A formulation patent can protect a specific combination of:

• Norethindrone acetate and ethinyl estradiol.
• Dose ratios.
• Tablet composition.
• Release profile.
• Stability profile.
• Manufacturing process.
• Use in menopausal hormone therapy.

Patent value depends on claim scope, expiration, terminal disclaimers, prosecution history, and whether the claims remain enforceable. For an old oral hormone product, the main practical barrier to generic entry is usually FDA approval, manufacturing validation, bioequivalence, and commercial scale rather than a durable formulation patent.

The FDA Orange Book should be checked for current patent and exclusivity listings associated with the applicable reference-listed drug. Orange Book entries can change by product and sponsor, and historical brand patent information should not be treated as current protection without a product-specific review.[4]

When does FEMHRT lose exclusivity?

FEMHRT’s core small-molecule exclusivity is mature. The relevant distinction is between:

• FDA regulatory exclusivity.
• Listed patent protection.
• Trademark and brand protection.
• Commercial availability.

FEMHRT does not have biosimilar exclusivity because it is a small-molecule drug, not a biologic. Generic applicants can use the ANDA pathway if they demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.[3]

A historical patent expiration date cannot establish current freedom to launch without reviewing the current Orange Book listing, litigation history, and any applicable pediatric or regulatory exclusivity. For mature products, generic applicants usually evaluate a Paragraph IV certification only if a listed patent remains relevant. If no relevant listed patent remains, the filing may proceed under a Paragraph III certification or a certification framework appropriate to the current Orange Book record.[4,5]

What Paragraph IV challenges and litigation affect FEMHRT?

A Paragraph IV challenge alleges that a listed patent is invalid, unenforceable, or not infringed. For FEMHRT, litigation risk should be assessed against the specific reference-listed drug and patent numbers appearing in the current Orange Book.

The commercial impact of a Paragraph IV filing depends on:

• Whether the sponsor sues within 45 days.
• Whether a 30-month stay applies.
• The number of ANDA filers.
• The strength of the challenged claims.
• Whether the product has meaningful remaining sales.
• Whether an authorized generic or settlement changes launch economics.

No biosimilar litigation pathway applies. Any litigation would concern small-molecule patents, ANDA approval, infringement, labeling, or market conduct.

Settlement agreements also require Federal Trade Commission and Department of Justice review under applicable filing requirements. A settlement may establish an agreed launch date, license rights, or other restrictions, but its value depends on the remaining commercial life of the product.[6]

How strong is the FEMHRT patent estate?

The patent estate should be viewed as commercially moderate to weak for new excipient entrants unless a live, enforceable patent covers a specific formulation or process.

Patent category	Relevance to excipient strategy	Expected barrier
Active-ingredient combination	May cover the drug combination or dose	Potentially material if still enforceable
Tablet formulation	Could restrict a specific excipient combination	Usually design-around possible
Manufacturing process	May cover granulation, blending, or compression	Site-specific risk
Method of use	May cover menopausal treatment claims	Labeling and carve-out considerations
Packaging or stability	May affect presentation or shelf life	Usually manageable through alternatives

Excipient suppliers should avoid supplying a formulation that copies a live claim limitation when a non-infringing alternative is available. Freedom-to-operate review should examine claim construction, prosecution history, continuation patents, and jurisdiction-specific expiry.

What generic launch risks exist for FEMHRT?

The main launch risks are technical and commercial.

Technical risks

• Failure to demonstrate bioequivalence.
• Dose uniformity problems caused by low-dose ethinyl estradiol.
• Dissolution differences from the reference product.
• Stability failures caused by moisture, light, or excipient interaction.
• Inconsistent tablet appearance between strengths.
• Supplier changes that trigger comparability work.

Regulatory risks

FDA review can focus on inactive-ingredient acceptability, bioequivalence, labeling, manufacturing controls, and data integrity. Excipient changes after approval may require a supplement depending on the scale and regulatory impact of the change.[3,7]

Commercial risks

FEMHRT is an established menopause product in a crowded therapeutic market. Competition includes generic norethindrone acetate/ethinyl estradiol products, estradiol-based products, progesterone combinations, transdermal systems, vaginal estrogen products, and nonhormonal therapies.

An excipient-led product must therefore deliver a measurable procurement or patient benefit. Lactose-free status, reliable supply, reduced tablet size, colorant avoidance, and consistent quality are more credible differentiators than generic claims of superior tolerability without clinical evidence.

How does FEMHRT compare with other menopausal hormone products?

Product type	Excipient opportunity	Regulatory complexity	Commercial differentiation
FEMHRT oral tablet	Lactose-free, low-dose uniformity, compact tablet	Standard ANDA pathway	Moderate
Estradiol/norethindrone oral products	Similar tablet optimization	Standard ANDA pathway	Moderate
Transdermal estrogen/progestin	Adhesive, permeation enhancer, backing layer	Higher product-performance burden	High
Vaginal estrogen	Mucoadhesive, preservative, local-delivery excipients	Formulation-specific	High
Progesterone capsules	Oil vehicle and softgel shell	Distinct dosage-form controls	Moderate
Nonhormonal oral products	Taste masking and modified release	Product-specific	Variable

FEMHRT is more accessible for conventional solid-dose generic development than transdermal or vaginal products. Its lower technical complexity also means that price competition is likely to be stronger.

What licensing and partnership opportunities exist?

The most plausible transactions are supply and development agreements rather than licenses to a proprietary FEMHRT excipient platform.

Potential structures include:

• Excipient supplier agreements with dual-source rights.
• Contract development and manufacturing of lactose-free tablets.
• Co-development of a generic ANDA.
• Technology transfer for low-dose blend uniformity.
• Regional commercialization rights.
• Authorized-generic supply arrangements.
• Portfolio licensing covering multiple menopausal hormone products.

A supplier with validated low-dose blending, direct-compression expertise, or regulatory support for global excipient changes may command more value than a supplier offering a marginally cheaper filler.

Key Takeaways

• FEMHRT is an oral combination of norethindrone acetate and ethinyl estradiol in two strengths.
• Its core exclusivity is mature, and its commercial value is primarily generic and supply-chain driven.
• The strongest excipient opportunity is a lactose-free, immediate-release tablet with reliable low-dose content uniformity.
• Co-processed excipients can improve manufacturability but may increase supplier and regulatory complexity.
• FEMHRT has no biosimilar pathway because it is a small-molecule drug.
• Paragraph IV and litigation risk depend on current Orange Book listings, not historical patent references.
• The main barriers are bioequivalence, blend uniformity, dissolution, stability, approval timing, and generic price competition.
• Excipient suppliers can create value through validated process performance, dual sourcing, and differentiated tablet platforms.

FAQs

Can a generic FEMHRT product use different excipients?

Yes. An ANDA may use different inactive ingredients if they are acceptable for the dosage form and the finished product demonstrates pharmaceutical equivalence, bioequivalence, quality, and stability.[3]

Is a lactose-free FEMHRT generic commercially viable?

Potentially. It can address excipient preferences and supply requirements, but commercial viability depends on reimbursement, generic competition, manufacturing cost, and pharmacy substitution.

Does FEMHRT have a biologic or biosimilar competitor?

No. FEMHRT contains synthetic small-molecule hormones. Competitors proceed through generic-drug pathways rather than the biosimilar pathway.

Which excipient creates the greatest technical risk?

The largest technical risk usually arises from the interaction of filler, binder, disintegrant, and lubricant choices with low-dose content uniformity and dissolution. The active dose of ethinyl estradiol is particularly important for blend control.

Can a new manufacturer launch without a Paragraph IV challenge?

Yes, depending on the current Orange Book patent record. The applicable certification may be Paragraph III, Paragraph IV, or another certification required by the listed patent status.[4,5]

References

1. U.S. Food and Drug Administration. (n.d.). FEMHRT (norethindrone acetate and ethinyl estradiol) prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: FEMHRT norethindrone acetate and ethinyl estradiol tablet.
3. U.S. Food and Drug Administration. (2014). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
5. U.S. Food and Drug Administration. (n.d.). Patent certifications and 30-month stays under the Hatch-Waxman Act.
6. Federal Trade Commission. (n.d.). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act.
7. U.S. Food and Drug Administration. (2019). Changes to an approved NDA or ANDA: Guidance for industry.